Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

J Clin Pharm Ther. 2018 Dec;43(6):906-909. doi: 10.1111/jcpt.12727. Epub 2018 Jun 28.

Abstract

What is known and objective: No studies have evaluated the use of sorafenib with the direct-acting antiviral ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV).

Case summary: Three hepatitis C virus genotype 1b-infected patients with well-preserved liver function were included in this prospective case series. The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV/PTV/r+DSV for 12 weeks. One patient discontinued sorafenib while concomitant treatment due to grade 2 fatigue and muscular pain. The other two patients reported only grade 1 adverse effects. Sustained virologic response at 24 weeks was achieved, and no tumour recurrences were found.

What is new and conclusion: The concurrent use of OBV/PTV/r+DSV with sorafenib was considered safe and effective.

Keywords: antiviral agents; drug interaction; hepatitis C; hepatocellular carcinoma; sorafenib.

Publication types

  • Case Reports

MeSH terms

  • 2-Naphthylamine
  • Aged
  • Anilides / administration & dosage
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / adverse effects
  • Carbamates / administration & dosage
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / pathology
  • Cyclopropanes
  • Drug Therapy, Combination
  • Female
  • Genotype
  • Hepacivirus / genetics*
  • Hepacivirus / isolation & purification
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Lactams, Macrocyclic
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / pathology
  • Macrocyclic Compounds / administration & dosage
  • Male
  • Middle Aged
  • Proline / analogs & derivatives
  • Prospective Studies
  • Ritonavir / administration & dosage
  • Sorafenib / administration & dosage
  • Sorafenib / adverse effects
  • Sulfonamides / administration & dosage
  • Treatment Outcome
  • Uracil / administration & dosage
  • Uracil / analogs & derivatives
  • Valine

Substances

  • Anilides
  • Antineoplastic Agents
  • Antiviral Agents
  • Carbamates
  • Cyclopropanes
  • Lactams, Macrocyclic
  • Macrocyclic Compounds
  • Sulfonamides
  • ombitasvir
  • Uracil
  • Proline
  • Sorafenib
  • 2-Naphthylamine
  • dasabuvir
  • Valine
  • Ritonavir
  • paritaprevir